KR100817967B1 - 종양 괴사 인자-관련 세포사멸-유도성 리간드 수용체에 선택적인 항체 및 그의 용도 - Google Patents

종양 괴사 인자-관련 세포사멸-유도성 리간드 수용체에 선택적인 항체 및 그의 용도 Download PDF

Info

Publication number
KR100817967B1
KR100817967B1 KR1020027014707A KR20027014707A KR100817967B1 KR 100817967 B1 KR100817967 B1 KR 100817967B1 KR 1020027014707 A KR1020027014707 A KR 1020027014707A KR 20027014707 A KR20027014707 A KR 20027014707A KR 100817967 B1 KR100817967 B1 KR 100817967B1
Authority
KR
South Korea
Prior art keywords
delete delete
antibody
cells
variable region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027014707A
Other languages
English (en)
Korean (ko)
Other versions
KR20030055177A (ko
Inventor
통 조우
기미히사 이치카와
로버트 피 킴벌리
윌리암 제이 쿠프만
Original Assignee
유에이비 리서치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유에이비 리서치 파운데이션 filed Critical 유에이비 리서치 파운데이션
Publication of KR20030055177A publication Critical patent/KR20030055177A/ko
Application granted granted Critical
Publication of KR100817967B1 publication Critical patent/KR100817967B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
KR1020027014707A 2000-05-02 2001-05-02 종양 괴사 인자-관련 세포사멸-유도성 리간드 수용체에 선택적인 항체 및 그의 용도 Expired - Lifetime KR100817967B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20134400P 2000-05-02 2000-05-02
US60/201,344 2000-05-02
PCT/US2001/014151 WO2001083560A1 (en) 2000-05-02 2001-05-02 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020067015043A Division KR20060092292A (ko) 2000-05-02 2001-05-02 종양 괴사 인자-관련 세포소멸-유도성 리간드 수용체에선택적인 항체 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20030055177A KR20030055177A (ko) 2003-07-02
KR100817967B1 true KR100817967B1 (ko) 2008-03-31

Family

ID=22745456

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020067015043A Ceased KR20060092292A (ko) 2000-05-02 2001-05-02 종양 괴사 인자-관련 세포소멸-유도성 리간드 수용체에선택적인 항체 및 그의 용도
KR1020027014707A Expired - Lifetime KR100817967B1 (ko) 2000-05-02 2001-05-02 종양 괴사 인자-관련 세포사멸-유도성 리간드 수용체에 선택적인 항체 및 그의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020067015043A Ceased KR20060092292A (ko) 2000-05-02 2001-05-02 종양 괴사 인자-관련 세포소멸-유도성 리간드 수용체에선택적인 항체 및 그의 용도

Country Status (27)

Country Link
US (6) US7244429B2 (enExample)
EP (4) EP2065400B1 (enExample)
JP (4) JP4156238B2 (enExample)
KR (2) KR20060092292A (enExample)
CN (2) CN101585881B (enExample)
AT (1) ATE426615T1 (enExample)
AU (2) AU5936601A (enExample)
BG (3) BG65929B1 (enExample)
BR (1) BR0110547A (enExample)
CA (1) CA2407965C (enExample)
CY (1) CY1109179T1 (enExample)
CZ (2) CZ304614B6 (enExample)
DE (1) DE60138097D1 (enExample)
DK (1) DK1287035T3 (enExample)
EE (1) EE05548B1 (enExample)
ES (1) ES2323448T3 (enExample)
HU (2) HU229417B1 (enExample)
IL (1) IL152605A0 (enExample)
MX (1) MXPA02010823A (enExample)
NO (2) NO329843B1 (enExample)
NZ (1) NZ522881A (enExample)
PL (1) PL211733B1 (enExample)
PT (1) PT1287035E (enExample)
RU (1) RU2298013C2 (enExample)
TW (1) TWI318983B (enExample)
WO (1) WO2001083560A1 (enExample)
ZA (1) ZA200209230B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
ES2281126T3 (es) 1997-03-17 2007-09-16 Human Genome Sciences, Inc. Receptor 5 que contiene un dominio de muerte.
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
JP2002543151A (ja) * 1999-05-04 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
ES2437992T3 (es) 2001-05-25 2014-01-15 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
CN101570764A (zh) 2001-10-19 2009-11-04 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
IL161686A0 (en) * 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
CA2471140A1 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
DE10210427A1 (de) 2002-03-09 2003-10-09 Hans Konrad Mueller-Hermelink Humaner monoklonaler Antikörper
US7772372B2 (en) 2002-07-04 2010-08-10 Patrys Limited Neoplasm specific antibodies and uses thereof
AU2008201431B2 (en) * 2002-11-27 2011-11-24 Irm, Llc Methods and compositions for inducing Apoptosis in cancer cells
KR20090046973A (ko) * 2002-11-27 2009-05-11 아이알엠 엘엘씨 암세포에서 세포자멸사를 유도하기 위한 방법 및 조성물
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
WO2005092927A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
CN100427505C (zh) * 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
CN102977205A (zh) * 2004-12-13 2013-03-20 赛弗隆澳大利亚(Vic)私人有限公司 骨保护素变异蛋白
BRPI0606791A2 (pt) 2005-02-02 2010-02-09 Uab Research Foundation métodos de reverter ou prevenir a resistência de uma célula a um agonista do receptor da morte, de triar uma célula quanto a um biomarcador da resistência a um agonista do receptor da morte, de monitorar a resistência a um agonista do receptor da morte em um indivìduo, de induzir seletivamente a apoptose em uma célula alvo expressando um receptor da morte, de tratar de um indivìduo com cáncer, de tratar de um indivìduo com uma doença inflamatória ou autoimune, de bloquear a ligação da proteìna contendo card a um receptor da morte em uma célula, de bloquear a associação de um iap com o receptor da morte e de triar um modulador de uma proteìna contendo card, composição, ácido nucleico isolado, vetor, célula, e, polipeptìdeo isolado
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
JP5004154B2 (ja) * 2005-04-06 2012-08-22 一般財団法人化学及血清療法研究所 組換え抗ボツリヌス神経毒素抗体
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CN101300273B (zh) * 2005-08-31 2013-05-22 安姆根有限公司 Trail受体2多肽和抗体
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CN101605887B (zh) 2006-05-16 2012-09-05 协和发酵麒麟株式会社 蛋白的高分泌生产方法
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
KR100847010B1 (ko) * 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
KR100804126B1 (ko) 2007-02-09 2008-02-19 아주대학교산학협력단 종양 괴사 인자―관련 세포사멸―유도 리간드의 수용체에특이적으로 결합하는 1가의 인간 단일클론 항체 및 그의항원결합 단편
AR066913A1 (es) * 2007-06-08 2009-09-23 Irm Llc Metodos y composiciones para inducir la apoptosis en celulas cancerosas
JPWO2009020094A1 (ja) * 2007-08-09 2010-11-04 第一三共株式会社 疎水性分子で修飾した抗体
WO2009057813A1 (ja) 2007-10-31 2009-05-07 National Institute Of Advanced Industrial Science And Technology タンパク質の高分泌生産方法
WO2010047509A2 (ko) * 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
JP2013505944A (ja) * 2009-09-24 2013-02-21 シアトル ジェネティックス， インコーポレイテッド Ｄｒ５リガンド薬物結合体
US9068019B2 (en) 2009-10-19 2015-06-30 Hanall Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
KR20120101050A (ko) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 기저형 유전자형 암의 치료 방법
WO2011084623A1 (en) 2009-12-16 2011-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
RU2644678C1 (ru) * 2010-10-29 2018-02-13 Дайити Санкио Компани, Лимитед Новое антитело против dr5
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
CA2834776A1 (en) * 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2014018625A1 (en) * 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CN103074425B (zh) * 2012-12-29 2014-01-01 深圳市第三人民医院 Cd263基因的用途
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN104710533A (zh) * 2013-12-12 2015-06-17 中国科学院深圳先进技术研究院 sDR5-Fc融合蛋白及其用途
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
CN105061604B (zh) * 2015-08-19 2018-03-16 河南大学 sDR5‑Fc融合蛋白突变体及其应用
KR102791773B1 (ko) 2015-10-30 2025-04-03 갤럭시 바이오테크, 엘엘씨 사멸 수용체 4 및 사멸 수용체 5에 결합하는 매우 강력한 항체
CA3007031A1 (en) 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
CN106924735A (zh) * 2015-12-29 2017-07-07 上海交通大学医学院附属瑞金医院 多巴胺1类受体激动剂在制备肿瘤治疗药物中的用途
WO2017139485A1 (en) 2016-02-09 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
EP4043492A1 (en) 2016-03-01 2022-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2018138297A1 (en) 2017-01-27 2018-08-02 Kymab Limited Anti-opg antibodies
KR101926834B1 (ko) 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
KR101951025B1 (ko) 2017-08-17 2019-02-21 서울대학교산학협력단 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물
SG11202001401TA (en) * 2017-09-22 2020-04-29 Immunogen Inc Separation of triple-light chain antibodies using cation exchange chromatography
WO2019100193A1 (zh) * 2017-11-21 2019-05-31 深圳先进技术研究院 抗dr5的抗体及其制备方法和应用
WO2019100194A1 (zh) * 2017-11-21 2019-05-31 深圳先进技术研究院 抗dr5的抗体及其制备方法和应用
CN108251443A (zh) * 2018-01-23 2018-07-06 深圳市人民医院 一种tnfrsf10c重组质粒、制备方法及其应用
US12018045B2 (en) 2018-03-06 2024-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
CN117003874A (zh) 2018-03-20 2023-11-07 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
US20240382499A1 (en) 2021-01-15 2024-11-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009165A1 (en) * 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
ES2284199T5 (es) 1997-01-28 2011-11-14 Human Genome Sciences, Inc. Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l).
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
ES2281126T3 (es) 1997-03-17 2007-09-16 Human Genome Sciences, Inc. Receptor 5 que contiene un dominio de muerte.
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
IL123888A0 (en) 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
EP1007562A4 (en) 1997-04-16 2000-09-27 Millennium Pharm Inc TANGO-63d AND TANGO-63e PROTEINS RELATED TO THE TUMOR NECROSIS FACTOR RECEPTOR
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
JP2001510042A (ja) * 1997-07-15 2001-07-31 イミュネックス・コーポレーション Ｔｒａｉｌ受容体
US6833135B1 (en) 1997-08-06 2004-12-21 Laboratorio Medinfar Produtos Farmaceuticos, Lda. DNA integration into “Mycobacterium spp.” genome by trans-complementation using a site-specific integration system
AU8861898A (en) * 1997-08-13 1999-03-08 Ufe Solar Gmbh Sorption trap arrangement and method for storing heat
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
ES2286856T3 (es) 1997-09-12 2007-12-01 Biogen Idec Ma Inc. Receptores train ricos en cisteina.
US7105640B2 (en) * 1997-10-17 2006-09-12 Genentech, Inc. Anti-pro792 antibodies
ATE517125T1 (de) 1998-01-26 2011-08-15 Genentech Inc ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
US20040120947A1 (en) 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
JP4716578B2 (ja) 1999-04-12 2011-07-06 ジェネンテック， インコーポレイテッド 腫瘍壊死因子相同体及びそれをコードする核酸
JP2002543151A (ja) 1999-05-04 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 死ドメイン含有レセプター５
EP1178828A4 (en) 1999-05-06 2004-10-13 Human Genome Sciences Inc RECEPTOR CONTAINING "DEATH DOMAIN"
WO2000073349A1 (en) 1999-05-28 2000-12-07 Genentech, Inc. Dr4 antibodies and uses thereof
WO2000075191A2 (en) 1999-06-09 2000-12-14 Genentech, Inc. Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
IL148266A0 (en) 1999-09-15 2002-09-12 Genentech Inc Apo-2 receptor antibodies
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
CA2426710A1 (en) 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6965023B2 (en) * 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
CA2451680C (en) 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009165A1 (en) * 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof

Also Published As

Publication number Publication date
PL211733B1 (pl) 2012-06-29
DE60138097D1 (de) 2009-05-07
MXPA02010823A (es) 2004-05-05
BG109275A (en) 2006-10-31
JP2004502409A (ja) 2004-01-29
BR0110547A (pt) 2004-06-22
CZ2006291A3 (cs) 2017-11-01
EP2065400A3 (en) 2009-07-22
EP1287035A4 (en) 2004-09-29
NO338228B1 (no) 2016-08-08
PL366195A1 (en) 2005-01-24
RU2002132255A (ru) 2005-01-20
US20120076792A1 (en) 2012-03-29
CA2407965A1 (en) 2001-11-08
JP2007091749A (ja) 2007-04-12
US20030190687A1 (en) 2003-10-09
EP2065401A2 (en) 2009-06-03
BG66153B1 (bg) 2011-08-31
ZA200209230B (en) 2004-03-16
HU0500800D0 (en) 2005-10-28
HUP0400951A2 (hu) 2004-07-28
JP2009005707A (ja) 2009-01-15
CZ304614B6 (cs) 2014-08-06
EP2368910A1 (en) 2011-09-28
US20140308288A1 (en) 2014-10-16
TWI318983B (en) 2010-01-01
KR20030055177A (ko) 2003-07-02
HU229417B1 (hu) 2013-12-30
EP1287035A1 (en) 2003-03-05
IL152605A0 (en) 2003-06-24
ATE426615T1 (de) 2009-04-15
CN101585881A (zh) 2009-11-25
US7790165B2 (en) 2010-09-07
EP2368910B1 (en) 2016-02-10
DK1287035T3 (da) 2009-06-15
HU230399B1 (hu) 2016-04-28
CN100497388C (zh) 2009-06-10
EE05548B1 (et) 2012-06-15
JP4575975B2 (ja) 2010-11-04
NO20054145L (no) 2002-12-18
EP2065401A3 (en) 2009-07-22
CZ306996B6 (cs) 2017-11-01
NO329843B1 (no) 2011-01-10
EP1287035B1 (en) 2009-03-25
KR20060092292A (ko) 2006-08-22
EP2065400B1 (en) 2014-11-05
RU2298013C2 (ru) 2007-04-27
AU2001259366B2 (en) 2005-09-08
ES2323448T3 (es) 2009-07-16
US7244429B2 (en) 2007-07-17
AU5936601A (en) 2001-11-12
NZ522881A (en) 2005-05-27
BG65929B1 (bg) 2010-05-31
NO20025253D0 (no) 2002-11-01
HK1162524A1 (en) 2012-08-31
EP2065400A2 (en) 2009-06-03
JP2005232187A (ja) 2005-09-02
HK1126506A1 (en) 2009-09-04
CY1109179T1 (el) 2014-07-02
US8067001B2 (en) 2011-11-29
US20110008324A1 (en) 2011-01-13
PT1287035E (pt) 2009-06-30
EE200200621A (et) 2004-06-15
US8715668B2 (en) 2014-05-06
WO2001083560A1 (en) 2001-11-08
US20070298039A1 (en) 2007-12-27
CZ20023917A3 (cs) 2003-05-14
NO20025253L (no) 2002-12-18
EP2065401B1 (en) 2016-08-10
JP3892466B2 (ja) 2007-03-14
CA2407965C (en) 2014-10-14
BG107275A (bg) 2004-09-30
US8329180B2 (en) 2012-12-11
US9700618B2 (en) 2017-07-11
HK1050372A1 (en) 2003-06-20
JP4156238B2 (ja) 2008-09-24
US20130243780A1 (en) 2013-09-19
HUP0400951A3 (en) 2012-09-28
CN1440424A (zh) 2003-09-03
CN101585881B (zh) 2014-11-26

Similar Documents

Publication Publication Date Title
KR100817967B1 (ko) 종양 괴사 인자-관련 세포사멸-유도성 리간드 수용체에 선택적인 항체 및 그의 용도
KR101004098B1 (ko) 종양 괴사 인자-관련 세포사멸-유도 리간드 수용체에선택적인 항체 및 그의 용도
KR20040081422A (ko) 종양 괴사 인자-관련 세포사멸-유도 리간드 수용체에선택적인 항체와 다른 치료제와의 복합물
AU2001259366A1 (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20030198637A1 (en) Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
HK1126506B (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
HK1050372B (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
HK1162524B (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
HK1126505A (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021101

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20040702

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060525

Patent event code: PE09021S01D

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20060725

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20061127

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070502

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20071031

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20070502

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20061127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20060525

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20071130

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20071031

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080107

Appeal identifier: 2007101012251

Request date: 20071130

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20071130

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20071130

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070702

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070126

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20060725

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20040702

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20080107

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20080102

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080324

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080324

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110217

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20120305

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130305

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130305

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140228

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140228

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20150226

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20150226

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20160218

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160218

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180309

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20180309

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20190313

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20190313

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20200312

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20200312

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20210316

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20211102

Termination category: Expiration of duration